» Articles » PMID: 32051396

PDL1 Blockage Increases Fetal Resorption and Tfr Cells but Does Not Affect Tfh/Tfr Ratio and B-cell Maturation During Allogeneic Pregnancy

Overview
Journal Cell Death Dis
Date 2020 Feb 14
PMID 32051396
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A successful pregnancy requires sophisticated regulation of uterine microenvironment to guarantee the existence of semi-allogeneic conceptus without immune rejection. T follicular regulatory (Tfr) cells exert a suppressive effect on Tfh-cell expansion, B-cell response, and antibody production. Although accumulating evidence has demonstrated that dysregulations of Tfr cells can bring on various immunological diseases, their immunomodulatory roles during pregnancy still remain unheeded. Herein, we introduced an allogeneic normal-pregnant mouse model and found that CD4CXCR5PD-1Foxp3 Tfr cells were preferentially accumulated in the uterus at mid-gestation and displayed a distinct phenotype. In addition, the absence of PDL1 resulted in increased fetal resorption by favoring Tfr cells accumulation and upregulating PD-1 expression on these cells. However, PDL1 blockade affected neither the ratio of Tfh/Tfr cells nor the maturation and differentiation of B cells. Overall, our results are the first to present a correlation of Tfr cells accumulation with healthy allogeneic pregnancy and PDL1 blockade-induced miscarriage, and to indicate that appropriate assembly of Tfr cells is important for pregnancy maintenance. Since blockade of PD-1-PDL1 pathway leads to more Tfr cells and fetal losses, the reproductive safety must be taken into consideration when PD-1/PD-L1 checkpoint blockade immunotherapy is used in pregnancy.

Citing Articles

Chronic viral infection impairs immune memory to a different pathogen.

Yang C, Liu Z, Yang Y, Cocka L, Li Y, Zeng W PLoS Pathog. 2024; 20(3):e1012113.

PMID: 38547316 PMC: 11003680. DOI: 10.1371/journal.ppat.1012113.


What role does PDL1 play in EMT changes in tumors and fibrosis?.

Zhang Y, Zhang Y, Wang Y, Zhao Y, He L Front Immunol. 2023; 14:1226038.

PMID: 37649487 PMC: 10463740. DOI: 10.3389/fimmu.2023.1226038.


Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases.

Braga A, Balthar E, Souza L, Samora M, Rech M, Madi J Clinics (Sao Paulo). 2023; 78:100260.

PMID: 37523979 PMC: 10404605. DOI: 10.1016/j.clinsp.2023.100260.


Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients.

Kumar S, Chatterjee M, Ghosh P, Ganguly K, Basu M, Ghosh M Genes Dis. 2023; 10(4):1318-1350.

PMID: 37397537 PMC: 10311058. DOI: 10.1016/j.gendis.2022.07.024.


Effects of quercetin on immune regulation at the maternal-fetal interface.

Fu Z, Tian Y, Zhou X, Lan H, Wu S, Lou Y Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 52(1):68-76.

PMID: 37283120 PMC: 10293775. DOI: 10.3724/zdxbyxb-2022-0499.


References
1.
Negishi Y, Takahashi H, Kuwabara Y, Takeshita T . Innate immune cells in reproduction. J Obstet Gynaecol Res. 2018; 44(11):2025-2036. DOI: 10.1111/jog.13759. View

2.
Schumacher A, Sharkey D, Robertson S, Zenclussen A . Immune Cells at the Fetomaternal Interface: How the Microenvironment Modulates Immune Cells To Foster Fetal Development. J Immunol. 2018; 201(2):325-334. DOI: 10.4049/jimmunol.1800058. View

3.
PrabhuDas M, Bonney E, Caron K, Dey S, Erlebacher A, Fazleabas A . Immune mechanisms at the maternal-fetal interface: perspectives and challenges. Nat Immunol. 2015; 16(4):328-34. PMC: 5070970. DOI: 10.1038/ni.3131. View

4.
Arck P, Hecher K . Fetomaternal immune cross-talk and its consequences for maternal and offspring's health. Nat Med. 2013; 19(5):548-56. DOI: 10.1038/nm.3160. View

5.
Sharpe A, Pauken K . The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2017; 18(3):153-167. DOI: 10.1038/nri.2017.108. View